Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 6thEuro-Global Conference on Infectious Diseases Paris, France.

Day 1 :

Conference Series Euro Infectious Diseases 2017 International Conference Keynote Speaker Ishwar Gilada photo

Dr. Ishwar Gilada is a medical doctor, specialized in Skin & STDs with special training in HIV management, founder of India’s first private sector comprehensive HIV Care clinic; President of AIDS Society of India and is Secretary General of Peoples Health Org. (India). He was the Jt. Sec. of National AIDS Committee, Govt of India (1995-97). He was the first to raise alarm against AIDS in 1985, is known for bringing India on AIDS control map, had started India’s first AIDS Clinic-1986 and has expertise in HIV care in resource-poor settings. He had trained several doctors, nurses and social workers; he was Editor-Publisher of AIDS ASIA from 1993 to 2008.  He initiated, managed, supervised, evaluated over 40 HIV/AIDS projects in India, addressed over 3700 public meetings and training programs in India and abroad, has 280 scientific papers at conferences, written chapters in books on AIDS/STDs.  He was consultant for American Foundation for AIDS Research (AmFAR), World Vision, USAID; has more than 65 awards to his credit including the "Outstanding Young Person of the World" –Glasgow in 1995 and Annemarie Madison Award-Germany in 1999 in Munich, Germany where he was termed as ‘the Indian Machinegun against AIDS’.


The global AIDS Epidemic has completed 36 years of its devastating presence killing over 35 million people. Yet India has brought hope to millions, for making HIV- a chronic, manageable and affordable disorder. Last decade has witnessed astounding evolution in ART, from treating few to ‘Treat-All’ culminating in the WHO’s 90-90-90 by 2020 target, piggybacking on India’s strength. 

Fixed dose combination like anti-TB treatment, invented in India made ART affordable @1% of innovators’ cost, accessible– meets 80% of global ART and easier with single-dose regimen. Innovators called Indian Generics copy-cats. When ‘West copies East’, why apply different yardsticks? Indian pharma risked inviting litigations, circumvented patents using reverse engineering and steadily brought down cost, with 100% bio-equivalence. Cheapest FDC annual cost is down from US$ 10,439/- per patient to $69.

‘Magic’ cure for HIV is distant, but there are strategies and possibilities to end the epidemic. Indian ARVs are available including the newest Dolutegravir @2% of innovator’s cost. For HCV cure, full course Sofosbuvir costs USD 84,000 globally, but in India its USD 1000 per patient through innovator’s voluntary licenses and USD 300 by patent violator, @0.3% of International cost!

Treating HIV-HCV is a public health imperative to prevent new transmissions, morbidity and mortality and delay will have grave public health consequences. Imagine a scenario of millions of HIV-HCV infections, minus India! Millions more would have died leading African continent towards extinction! The world recognised the Indian pharma strength in saving millions for decades from range of health issues only after HIV.

Conclusion: In patents versus patients, the balance tilts towards patients to bridge the enormous gap. Its a herculean task and will only be possible by an intensive and joint efforts of all including innovators. India will continue humanitarian mission to make life saving medicines affordable and accessible.

Conference Series Euro Infectious Diseases 2017 International Conference Keynote Speaker Catherine Mullié photo

Catherine Mullié obtained a PhD in Microbiology and a PharmD at the University of Lille, France, in 1999. After a post-doc year at the Faculté de Medicine in Amiens (Laboratoire d’Immunologie, INSERM-EMI 0351), she was appointed as assistant professor at the Faculté de Pharmacie in Amiens in 2000 and joined the LG-2A (Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, UMR 7378 CNRS) in 2008. She has been a member of the French Society for Microbiology since 2000. Her research is focused on the development of new antimicrobial and antimalarial drugs, with a special interest in efflux-mediated antibiotic resistance in Pseudomonas aeruginosa and Acinetobacter baumannii. She currently heads the French part of a bilateral project funded by France and Algeria (Partenariat Hubert Curien Tassili) on this topic.


Statement of the Problem: Pseudomonas aeruginosa is a Gram-negative ubiquitous microorganism found in various environmental niches as well as in human infections. It is innately resistant to a large number of commercially available antibiotics and has acquired a wide array of resistance mechanisms, tremendously complicating the clinical handling of P. aeruginosa infections. Antibiotic resistance can be mediated by several molecular mechanisms, one of them being the efflux of antibiotics from the bacterium through efflux pumps. In P. aeruginosa, antibiotic efflux is mainly mediated by pumps belonging to the Resistance-Nodulation-Division family: MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM. This work aimed to compare their expression in environmental and clinical strains of P. aeruginosa from Algeria and France either resistant or susceptible to fluoroquinolones to evaluate whether expression patterns would vary according to the sample origin and/or country.

Material & Methods: Clinical strains were collected from Amiens & Lille hospitals for France and Saida hospital for Algeria. Environmental strains were mostly isolated from water samples. Susceptibility to ciprofloxacin was evaluated by E-test and the broth microdilution method with and without an efflux inhibitor. Efflux pumps expression was then measured through a qRT-PCR experiment, using mexBmexDmexF and mexY as target genes.

Findings: 149 clinical and 30 environmental P. aeruginosa strains were included.  According to EUCAST breakpoints, 29.8% and 11.1% of French and Algerian clinical strains were resistant to ciprofloxacin, respectively. None of the environmental strains were resistant to ciprofloxacin. Analysis of qRT-PCR data showed that mexY expression was significantly increased in a majority of ciprofloxacin-resistant clinical strains while mexA was decreased.   

Conclusion & Significance: This study showed that ciprofloxacin-resistant strains were more common in clinical P. aeruginosa isolates than in environmental one.  The design of efflux inhibitors targeting MexXY-OprM efflux pump could therefore be of use to restore the activity of known antibiotics.

Keynote Forum

Janak Kishore

Sanjay Gandhi Post-graduate Institute of Medical Sciences, India.

Keynote: Clinical Impact of Parvovirus B19: Pioneer work from India Projecting B19 as Multi-Organ Disease Afflicter
Conference Series Euro Infectious Diseases 2017 International Conference Keynote Speaker Janak Kishore  photo

Professor Janak Kishore is Chief of Serology and Molecular Virology in the department of Microbiology, Sanjay Gandhi Post-graduate Institute of Medical Sciences, India. He was Associate Editor Indian Journal of Virology, member National Academy Medical Sciences, American societies and Fellow of JICA, Japan. His passion is on healing and minimising human sufferings; on unveiling emerging viral infections and finding aetiologies in viral epidemics and in investigating undiagnosed/missed clinical infections so that appropriate treatment is given and life is saved. Dr. Kishore taught for over 30 yrs with pioneer work on parvovirus B19, developed in-house molecular techniques and published three novel clinical associations besides finding novel oncolytic property of B19. He also worked on cytomegalovirus, enteroviral haemorrhagic conjunctivitis, rubella. Dr Kishore published over 50 papers, served as reviewer for reputed journals, organized conferences, Chaired sessions and frequently invited to speak at international conferences.


Parvovirus B19 (B19) causes myriads of clinical diseases depending hosts immunological and haematological status. Still most B19 infections underdiagnosed and seldom treated and largely ignored due to undefined clinical impact and its sinister complications besides limited diagnostic facilities and high cost of treatment by I.V.I.G. and even lack of awareness in clinicians of all varied spectrum of B19 clinical manifestations are additional riders. Cryptically, B19 causes significant morbidity/mortality and remains unrecognized global health problem. To unveil, we developed in-house diagnostic tools like DNA extraction from serum samples, PCR, nested-PCR, IgM ELISA and IgG ELISA for specific detection of B19 DNA and IgM antibodies to determine cases with acute infections and past infection. Then we determined B19 seroprevalence among 1000 voluntary blood donors and found 39.9% to be seropositive. Now this means that remaining 60% of Indians population and similarly half of world adult population are at risk of acquiring B19 infections. We reported B19 cases ending fatally with pure red cell aplasia, anaemia/thrombocytopenia with hepatitis and hemophagocytic syndrome. We detected B19 infections in 27.5% juvenile rheumatoid arthropathy (n=69), 19.8% recurrent aborters (n=116) in contrast to 11% of 136 pregnant-women and 5% of 120 non-pregnant women; another report found B19 in 60% high-risk pregnant women (n=60), 17.1% paediatric haematological malignancies (n=35), 41% beta-thalassemia major (n=90) besides transmission through donor units. Our novel clinical associations of B19 included cases of amegakaryocytic thrombocytopenia, myositis, non-occlusive ischemic gangrene of stomach/bowel besides novel oncolytic property of B19. Cumulatively our data found 21.2% (135 of 639 cases) B19 infected patients. B19 primarly recognized as tropic for erythroid progenitors due to binding to Gb4Cer and α5β1 integrins receptors. This first  review highlights recent data by which B19 is actually causing non-erythroid and multi tissue or multiorgan disease owing to ability of B19 binding  to multiple glycosphingolipids distributed widely; additionally  B19 can  infect vascular endothelial cells that lines all blood vessels hence can affect major organs by causing endothelilitis and vasculitic injuries. Cytotoxicity, nuclease, helicase, gene transactivation by B19 NS1, antibody-dependent enhancement are basic mechanisms. Hence B19 infections should be investigated recognised, treated besides efforts on B19 vaccine.